



using oxidants such as chloramine T (CT)<sup>8~10)</sup> and lactoperoxidase<sup>11~13)</sup> or by electrochemical methods.<sup>14,15)</sup> The conjugation method employs the chemical modification of h-TSH with a <sup>125</sup>I-labelled ester<sup>16)</sup>.

To date, h-TSH\* has been most frequently prepared by the conventional method originally developed by Greenwood and coworkers<sup>17)</sup>, which uses a large amount of CT and a relatively short reaction period (20–30 sec at 4°C). This method, however, imposes several experimental difficulties for reproducible and dependable labelling. As the reaction completes within a very short period of time, thorough mixing of the reaction mixture to ensure uniform labelling is usually difficult. In addition, the use of a large amount of an oxidant may cause the polymerization of the protein<sup>18,19)</sup> and oxidize chemically susceptible functional groups of the hormone, leading to a completely altered immunological behavior<sup>20~22)</sup>.

We have attempted to label h-TSH in the presence of a small amount of CT in order to overcome these difficulties. The labelling procedure developed in this laboratory and the radioimmunoassay based on the h-TSH\* prepared by the new method are reported in this paper.

## EXPERIMENTAL SECTION

### Materials and Reagents

(1) highly purified h-TSH (6 U/mg): This hormone was the product of Biodata, Italy. When used in the radiolabelling experiments, h-TSH was dissolved in water. The pH and the buffer capacity of the resulting solution was not explicitly specified by the producer.

(2) radioactive iodide: IMS 30 carrier-free <sup>125</sup>I- in sodium hydroxide, at a concentration of 100–240 mci/ml was purchased from The Radio Chemical Centre, Amersham, Bucks, U.K.

(3) reagents used for radioimmunoassay: Radioimmunoassay kits including standard h-TSH solution (320 U/ml), anti h-TSH rabbit serum, and anti rabbit  $\beta$ -globulin goat serum were purchased

from Daiichi, Japan. Normal rabbit serum is essential for the precipitation of the antibody complexes in the radioimmunoassay of h-TSH. It was found that normal rabbit serum was mixed with h-TSH\* in the Daiichi kit. Thus, normal rabbit serum was purchased from Biodata, Italy and used for the examination of the immunological behavior of h-TSH\* prepared in this laboratory.

(4) chloramine T and sodium metabisulfite: These were of reagent grade, and the respective aqueous solutions were freshly prepared prior to being used.

(5) buffers: Buffer A; 0.3M sodium phosphate at pH 7.5, buffer B; 0.03M sodium phosphate at pH 7.5, buffer C; 0.03M sodium phosphate and 0.25% BSA at pH 7.5,


(6) Sephadex G-75: This was the product of Pharmacia, Sweden.

### <sup>125</sup>I- Labelling of h-TSH

(1) using a large amount of CT at 4°C: Labelling of h-TSH by the method of Greenwood and coworkers was carried out by using a large amount of CT as the oxidant. To a mixture of Na <sup>125</sup>I (1 mci/10  $\mu$ l) and h-TSH (15  $\mu$ g/10  $\mu$ l water), CT (88  $\mu$ g/10  $\mu$ l buffer B) was added and the the resulting solution was stirred at 4°C for 30 sec. The reaction was quenched by the addition of sodium metabisulfite (240  $\mu$ g/100  $\mu$ l buffer B) and, subsequently, potassium iodide (1 mg/100  $\mu$ l buffer B). The product mixture was then separated on a Sephadex G-75 column at 4°C.

(2) using a small amount of CT at 25°C: To a mixture of buffer A (10  $\mu$ l), Na <sup>125</sup>I (0.1–0.7 mci/10  $\mu$ l) and h-TSH (1–15  $\mu$ g/10  $\mu$ l water), CT (0.5–1.8  $\mu$ g/10  $\mu$ l buffer A) was added. The resulting solution was well stirred for 12–15min at 25°C before being applied to a Sephadex G-75 column. The iodination reaction was sometimes quenched by adding sodium metabisulfite (5  $\mu$ g/10  $\mu$ l buffer B) prior to the separation on the Sephadex column. The labelling reaction was performed in a glass tube (4 x 30 mm) which contained a small wire piece as a magnetic stirring bar.

Scheme 1



(3) trichloroacetic acid (TCA) precipitation of h-TSH: During the course of the radiolabelling of h-TSH at 25°C, 1  $\mu$ l aliquots of the reaction mixture were removed and added to 1 ml solutions of KI (50  $\mu$ g) in buffer C.

One ml of TCA is added to the resulting mixture, which was then centrifuged at 3,000 rpm for 15 min. From the radioactivity of the whole mixture and the precipitate, the degree of  $^{125}$ I-incorporation to h-TSH was calculated.

**Purification of h-TSH\***

Separation of h-TSH\* was carried out at 4°C with a Sephadex G-75 column (1 $\times$ 60 cm), eluting with buffer B at an elution rate of 0.5 ml/min. Fractions (1 ml) were collected in plastic tubes containing 50  $\mu$ l of buffer C. The radioactivity of each tube was measured by a counter equipped with a teletype (Packard Model 3320 3JA).

**Radioimmunoassay**

Two fractions with the largest radioactivity

were taken from the protein portion of the Sephadex chromatogram and diluted with buffer B. Portions (10<sup>6</sup> cpm/tube) of the h-TSH\* sample were stored at -20°C until they were used in radioimmunoassay. Radioimmunoassay of h-TSH was performed according to the method of the Daiichi kit, which is summarized in Scheme 1.

**Results and Discussion**

**Radiolabelling of h-TSH**

The chromatogram for the gel filtration of h-TSH\* which was prepared according to the conventional method using a large amount of CT (CT, 88  $\mu$ g/40  $\mu$ l; [CT]<sub>0</sub>/[I\*]<sub>0</sub>=800) is illustrated in Figure 1. The presence of small peaks following the major protein peak may be related to fragmented or damaged proteins. This chromatogram, when compared with that obtained previously in this laboratory<sup>23</sup>, reveals that radiolabelling with great excess of CT is hardly reproducible. Oxidation of




Fig. 1. Chromatogram for the Sephadex G-75 separation of h-TSH\* prepared by the conventional method.

iodide ion under this condition is very fast, the overall labelling being complete within 20–30 sec. Thus, the method of mixing the reactants would be crucial for obtaining reproducible results. As the degree of exposure of h-TSH to the large amount of the strong oxidant cannot be controlled strictly, the immunological activity of h-TSH\* would be reproduced by this method only with great difficulties.

In order to overcome these complications, radiolabelling of h-TSH was attempted using small amounts of CT (CT, 0.5–1.8  $\mu\text{g}/40 \mu\text{l}$ ;  $[\text{CT}]_0/[\text{I}^*]_0 = 10-150$ ). The reaction was carried out at 25°C, and the incorporation of radioactivity into h-TSH approaches plateau 10 min after the initiation of the reaction as illustrated in Figure 2. Uniform radiolabelling of h-TSH is ensured when the reaction proceeds this slowly because efficient mixing of the reactants can be achieved quite easily. A typical chromatogram for the Sephadex G-75 separation of h-TSH\* prepared by this method is illustrated in Figure 3. Six labelling experiments have been performed using various amounts of the reactants, all of which manifested chromatograms similar to that of Figure 3. The absence of small peaks after the major protein peak suggests that the damage of h-TSH during the radiolabelling reaction is minimal. Thus, it appears that the direct reaction of h-TSH with CT is not appreciable under the condition that iodide ion is oxidized very mildly.

The portion of radioactivity incorporated into h-TSH, ( $\text{I}^*$  bound to h-TSH)/(total radioactivity), was not affected appreciably when the amount of CT was fixed at  $1.6 \times 10^{-4} \text{M}$  and those of  $^{125}\text{I}$  and h-TSH were varied over  $1.1 \times 10^{-6} - 7.9 \times 10^{-6} \text{M}$  and  $0.2 \times 10^{-6} - 1.8 \times 10^{-6} \text{M}$  respectively. However, ( $\text{I}^*$  bound to h-TSH)/(total radioactivity) increased significantly, although not linearly, when  $[\text{I}^*]_0$  was fixed at 0.3 mCi and  $[\text{CT}]_0/[\text{I}^*]_0$  was raised from 10 to 40. Thus, the overall labelling efficiency appears to be affected directly by the initial concentration of CT instead of the molar ratios of CT,  $^{125}\text{I}$ , and h-TSH, under the conditions of the




Fig. 2. Degree of the incorporation of  $^{125}\text{I}$  into h-TSH as the labelling reaction proceeds in the presence of a small amount of CT.




Fig. 3. Atypical chromatogram for the Sephadex G-75 separation of h-TSH\* prepared in the presence of a small amount of CT.

present study.

Although bovine TSH has been  $^{125}\text{I}$ -labelled with a small amount of CT at room temperature<sup>24,25</sup>, the present results represent the first successful preparation of immunologically dependable h-TSH\* under such conditions. In the following sections, the characterization of the immunological behavior of h-TSH\* prepared at room temperature is discussed.

### Affinity to Antibody

The affinity of h-TSH\* to antibody was examined by measuring the radioactivity bound to the antibody in the absence of added standard h-TSH ( $B_0$ ). The ratio of  $B_0$  and the total radioactivity,  $B_0/T$ , was compared with the number of  $^{125}\text{I}$  atoms incorporated into a molecule of h-TSH\*,  $\#I^*/h\text{-TSH}^*$ , as illustrated in Fig. 4. The value of  $\#I^*/h\text{-TSH}^*$  was calculated from the total radioactivity of the protein fractions, that of the non-protein fractions, the initially added molar amount of  $^{125}\text{I}^-$ , and the initially added molar amount of h-TSH. The molar amount of h-TSH is calculated from the weight of h-TSH used in the labelling experiment and the molecular weight of h-TSH, but it was assumed that the commercial h-TSH is only 20% pure. This is because the highest activity of h-TSH reported in the literature is 30 U/mg while the activity of the commercial h-TSH used in the present investigation is 6 U/mg.

The value of  $B_0/T$  reaches the maximum when  $\#I^*/h\text{-TSH}^*$  is 1-2. Incorporation of less than one  $^{125}\text{I}$  atom leaves a significant portion of h-TSH unmodified, which competes with the modified




Fig. 4. A plot of  $B_0/T$  against the number of  $^{125}\text{I}$  atoms incorporated into a molecule of h-TSH\* ( $\#I^*/h\text{-TSH}^*$ ) for h-TSH\* prepared by the new method.

hormone for binding to the antibody. This is reflected in the small values of  $B_0/T$  for  $\#I^*/h\text{-TSH}^* < 1$ , as illustrated in Figure 4. When several  $^{125}\text{I}$  atoms are contained in a h-TSH\* molecule, the immunological behavior of the labelled hormone deviates greatly from that of the normal hormone. Much smaller  $B_0/T$  values for  $\#I^*/h\text{-TSH}^* > 3$  (Figure 4) indicate the lower affinity of multiply iodinated h-TSH.

The h-TSH\* sample provided in Daiichi kits for h-TSH radioimmunoassay revealed  $B_0/T$  of about 40% when tested immediately after arrival. The antibody affinity of h-TSH\* prepared by the present method, thus, can be brought above that of the commercial product by controlling the amounts of the reactants appropriately.

### Radioimmunoassay

As h-TSH\* prepared by the new method manifested satisfactory  $B_0/T$  values, its application to radioimmunoassay was tested according to the procedure described in the experimental section. A typical standard curve of  $B/T$  against the logarithm of the amount of added standard h-TSH,  $\log [h\text{-TSH}]$ , is illustrated in Figure 5. This demonstrates that h-TSH\* prepared in the present study is suitable for the radioimmunological estimation of h-TSH.




Fig. 5. A typical standard curve of  $B/T$  against the amount of standard h-TSH for radioimmunoassay with h-TSH\* prepared by the new method.

Radiolabelled proteins gradually lose their immunological activity due to radiation damage<sup>26)</sup> as well as radioactivity loss caused by the decay of the radioactive nuclide. When tested at an interval of one week, satisfactory radioimmunoassay results were obtained with h-TSH\* prepared by the new method until at least 6—7 weeks after preparation. This is comparable to the effective period (5—6 weeks) of h-TSH\* of the Daiichi Kit. Therefore, h-TSH\* prepared by the new method appears to be comparable to that of the commercial product in terms of B<sub>0</sub>/T and the effective life.

Clinical examination of h-TSH\* prepared by the new method will be the subject of the following paper.

#### Acknowledgment

This investigation was supported by grant from Seoul National University Hospital. The authors appreciate the expert technical assistance of Mr. Il-Tack Seo and Mr. Chul Soo Chang in the department of Nuclear Medicine, Seoul National University Hospital.

#### REFERENCES

- 1) Adams D.D. and Kennedy T.H.: *Measurements of the thyroid stimulating hormone content of serum from hypothyroid and euthyroid people. J. Clin. Endocr., 18, 325, 1968.*
- 2) Broughton A.: *Clinical usefulness of radioimmunoassay of thyrotropin: A review. Southern Med. J., 69, 702, 1976.*
- 3) Pekary A.E., Hershman J.M. and Parlow A.F.: *A sensitive and precise radioimmunoassay for human thyroid-stimulating hormone. J. Clin. Endocrinol. Metab., 41, 676, 1975.*
- 4) Utiger R.D.: *Radioimmunoassay of human plasma thyrotropin. J. Clin. Invest., 44, 1277, 1965.*
- 5) Wherry F.E., Pennington L.L., Bates R.W., Garrison M.M., Ehle A.Z. and Mason J.W.: *Immunological cross reactivity between monkey and human thyroid stimulating hormone as determined by radioimmunoassay: A rapid procedure for purifying labelled <sup>125</sup>I-TSH. Endocrinol. 86, 769, 1970.*
- 6) Hunter H.W.: *Preparation and Assessment of radioactive traces. Bri. Med. Bull., 30, 18, 1974.*
- 7) Bolton A.E. and Hunter W.M.: *J. Endocrinol, 55, XXXXXXI (Abstract) 1972.*
- 8) Hall R., Amos J., and Ormston B.J.: *Radioimmunoassay of human serum thyrotropin. Bri. Med. J., 13, 582, 1972.*
- 9) Nisula B.C. and Louvet J.P.: *Radioimmunoassay of thyrotropin concentrated from serum, J. Clin. Endocrinol. Metab., 46, 729, 1978.*
- 10) Spencer C.A. and Challand G.S.: *Interference in a radioimmunoassay for human thyrotropin. Clin. Chem., 23, 584, 1977.*
- 11) David G.S. and Reisfeld R.A.: *Protein iodination with solid state lactoperoxidase, Biochemistry, 13, 1014, 1974.*
- 12) Machalonis J.J., Cone R.E., and Santer V.: *Enzymic iodination. Biochem., 124, 921, 1971.*
- 13) Miyachi Y. Vaitukaitis, J.L., Nieschlag E. and Lipsett M.B.: *Enzymic radioiodination of gonadotropins. J. Clin. Endocr., 34, 23, 1972.*
- 14) Jovanovic V., Nemodoy D. and Lwin K.: *An effective electrolytic iodination of human serum albumin at alkaline pH. Int. J. App. Rad. Isop., 23, 242, 1972.*
- 15) Teare F.W. and Rosenberg R.A.: *Micro-electrolytic radioiodination of polypeptide hormones to high specific activity. Int. J. App. Rad. Isop., 29, 567, 1978.*
- 16) Bolton A.E. and Hunter W.M.: *The labelling of proteins to high specific radioactivities by conjugation to a <sup>125</sup>I-containing acylating agent. Biochem. J., 133, 529, 1973.*
- 17) Hunter W.M. and Greenwood F.C.: *Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature., 194, 495, 1962.*
- 18) Golaire J.G. and Vanhaelst L.: *Influence of the purification of <sup>125</sup>I-iodinated thyrotropin on the sensitivity of the radioimmunoassay. Int. J. App. Rad. & Isop., 21, 17, 1970.*

- 19) Sherman L.A., Harwig S., and Hayne O.A.: *Macromolecular complexes formed as the result of chloramine T radioiodination of proteins. Int. J. App. Rad. Isop.*, 25, 81, 1974.
- 20) Buckle R.M. In *Radioimmunoassay Methods: European Workshop* (Kirkham K.E. and Hunter W.M., eds.) 42~54. Churchill Livingstone, Edinburgh and London, 1971.
- 21) Moser R.J. and Hollingsworth D.R.: *Examination of some factors affecting sensitivity and reproducibility in radioimmunoassay of thyrotropin. Clin. Chem.*, 21, 347, 1975.
- 22) Pierce J.G. Liao T.H., and Carlsen R.B.: in *Li, C.H(ed) Hormonal Proteins and Peptides, Academic Press, New York. 189, 1973.*
- 23) Koh C.S., Lee H.K., Ro H.K., and Lee M.H.: *Radioimmunoassay of human thyrtropin Kor. J. Nuc. Med.*
- 24) Caro R.A., Ciscato V.A. De Giacomini S.M.V. and Quirogas.: *Labelling of proteins with <sup>125</sup>I and experimental determination of its sepcific activity. Int. J. App. Rad. Isotop.*, 26, 527, 1975.
- 25) Goldfine I.D., Amir S.M. Petersen A.W. and Ingbar S.H.: *Preparation of biologically active <sup>125</sup>I-TSH. Endocrinology*, 95, 1228, 1974.
- 26) Hotte C.E. and Ice R.D.: *The in vitro stabilty of (<sup>131</sup>I) O-Iodohippurate. J. Nucl. Med.*, 20, 441, 1979.